- Home
- CHRS vs WNEB Comparison
CHRS vs WNEB Comparison
Compare CHRS & WNEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- WNEB
- Stock Information
- Founded
- CHRS 2010
- WNEB 1853
- Country
- CHRS United States
- WNEB United States
- Employees
- CHRS 235
- WNEB N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- WNEB Savings Institutions
- Sector
- CHRS Health Care
- WNEB Finance
- Exchange
- CHRS Nasdaq
- WNEB Nasdaq
- Market Cap
- CHRS 134.4M
- WNEB 191.1M
- IPO Year
- CHRS 2014
- WNEB N/A
- Fundamental
- Price
- CHRS $1.16
- WNEB $9.35
- Analyst Decision
- CHRS Strong Buy
- WNEB Buy
- Analyst Count
- CHRS 4
- WNEB 3
- Target Price
- CHRS $5.38
- WNEB $9.75
- AVG Volume (30 Days)
- CHRS 2.4M
- WNEB 48.1K
- Earning Date
- CHRS 03-12-2025
- WNEB 01-28-2025
- Dividend Yield
- CHRS N/A
- WNEB 3.00%
- EPS Growth
- CHRS N/A
- WNEB N/A
- EPS
- CHRS N/A
- WNEB 0.56
- Revenue
- CHRS $304,340,000.00
- WNEB $73,385,000.00
- Revenue This Year
- CHRS $2.47
- WNEB N/A
- Revenue Next Year
- CHRS N/A
- WNEB $10.26
- P/E Ratio
- CHRS N/A
- WNEB $16.73
- Revenue Growth
- CHRS 44.19
- WNEB N/A
- 52 Week Low
- CHRS $0.66
- WNEB $6.00
- 52 Week High
- CHRS $2.87
- WNEB $10.08
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- WNEB 58.60
- Support Level
- CHRS $1.03
- WNEB $9.25
- Resistance Level
- CHRS $1.39
- WNEB $9.47
- Average True Range (ATR)
- CHRS 0.14
- WNEB 0.16
- MACD
- CHRS -0.03
- WNEB 0.06
- Stochastic Oscillator
- CHRS 14.04
- WNEB 76.71
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the Company's revenues, profits, and assets are derived by the Bank from banking products and services.